The article presents descriptions to drugs for multiple sclerosis (MS). It relates that gilenya can reduce relapse rate by 54% and slow progression of disability by 30% versus inactive placebo. Research confirmed that there were 58% fewer relapses and 32% less disability in a trial versus placebo with the intake of oral cladribine. Teriflunomide can be taken through a stand-alone therapy or used in combination with one of the standard disease-modifying drugs.
Processing Request
No Comments.